8.2.5. androgen deprivaton therapy. summary psychological impacts due use adt sexual function, mood, depression, cognitive function, impact partners found two clinical reviews . small rct evaluated qol one-year follow-up patients psa relapse primary therapy without evidence metastasis, various adt regimens, treatment. patients treated adt reported significant decline spatial reasoning, spatial abilities working memory well increased depression, tension, anxiety, fatigue, irritability treatment . conversely, prospective observational study follow-up three years failed demonstrate association cognitive decline men adt compared men pca treated adt healthy controls . prospective observational study locally advanced pca bcr local therapy found immediate adt associated lower overall qol compared deferred treatment . another retrospective non-randomised study suggested men receiving lhrh agonists reported worry physical discomfort poorer overall health less likely believe free cancer patients undergoing orchiectomy. stage diagnosis effect health outcomes . 8.2.5.1. sexual function cessation sexual activity common people undergoing adt, affecting 93% . androgen deprivation therapy reduces libido ability gain maintain erections. management acquired ed mostly non-specific . using specific non-validated questionnaire, bicalutamide monotherapy showed significant advantage castration domains physical capacity sexual interest (not sexual function) twelve months . post-hoc analysis, including patients sexual interest suggested bicalutamide associated better sexual preservation, including maintained sexual interest, feeling sexually attractive , preserved libido erectile function . 8.2.5.2. hot flushes hot flushes common side effect adt (prevalence estimated 44–80% men adt) . appear three months starting adt, usually persist long-term significant impact qol. serotonin re-uptake inhibitors (e.g., venlafaxine sertraline) appear effective men less hormone therapies based prospective rct comparing venlafaxine, 75 mg daily, medroxyprogesterone, 20 mg daily, cyproterone acetate, 100 mg daily . six months lhrh (n = 919), 311 men significant hot flushes randomised one treatments. based median daily hot-flush score, venlafaxine inferior -47.2% (interquartile range -74.3 -2.5) compared -94.5% (-100.0 -74.5) cyproterone group, -83.7% (-98.9 -64.3) medroxyprogesterone group. another rct (n = 78) compared oestradiol (transdermal 0,9mg 0,1% gel) placebo. six months oestradiol reduced daily hot flushes frequency (mean adjusted difference mad -1,6, p=0.04) effect weekly hot flushes significant (mad -19,6 p=0.11) . placebo effect influencing 30% patients , efficacy clonidine, veralipride, gabapentin acupuncture need compared prospective rcts. 8.2.5.3. non-metastatic bone fractures due increased bone turnover decreased bmd time-dependent manner, adt use linked increased risk fracture (up 45% rr long-term adt) . severe fractures men associated significant risk death . precise evaluation bmd performed dexa, ideally starting long-term adt. initial low bmd (t-score < -2.5 < -1, risk factors) indicates high risk subsequent non-metastatic fracture causes investigated. risk factors include increasing age, bmi 19 less, history previous fracture parent fractured hip, current smoking, use glucocorticoids, rheumatoid arthritis, alcohol consumption > two units per day, history falls number chronic medical conditions . fracture risk algorithms combine bmd clinical risk factors frax score used guide treatment decisions, uncertainty exists regarding optimal intervention threshold, therefore specific risk algorithm recommended men adt pca. obesity (increase body fat mass 10% and/or bmi > 30) sarcopenia (decrease lean tissue mass 3%) well weight loss common occur first year adt . changes increase fracture risk . suggested adding arta adt increase risk. also seen sr meta-analysis . found use arta associated increase fractures. eleven studies included total population 11,382 men (median [range] age: 72 [43-97] years), 6,536 arta group 4,846 control group. participants arta group could received enzalutamide, apalutamide, darolutamide combination androgen deprivation therapy enzalutamide combinations; patients control group could received placebo, bicalutamide, abiraterone. incidence fracture 242 fractures (4%) arta group 107 fractures (2%) control group. use arta associated increased risk fractures: all-grade fracture (rr, 1.59; 95% ci, 1.35-1.89; p <.001), likely grade 3 greater fracture (rr, 1.71; 95% ci, 1.12-2.63; p =.01). bicalutamide monotherapy may less impact bmd limited suboptimal efficacy m1 disease . intermittent lhrh-agonist modality might associated less bone impact . 8.2.5.4. metabolic effects lipid alterations common may occur early first three months treatment . androgen deprivation therapy also decreases insulin sensitivity increases fasting plasma insulin levels, marker insulin resistance. diabetic patients, metformin appears attractive option protection metabolic effects based retrospective analysis , insufficient data recommend use non-diabetic patients. metabolic syndrome association independent cardiovascular disease risk factors, often associated insulin resistance. definition requires least three following criteria : waist circumference > 102 cm;serum triglyceride > 1.7 mmol/l;blood pressure > 130/80 mmhg use medication hypertension;high-density lipoprotein (hdl) cholesterol < 1 mmol/l;glycaemia > 5.6 mmol/l use medication hyperglycaemia. prevalence metabolic-like syndrome higher adt compared men receiving adt . skeletal muscle mass heavily influences basal metabolic rate turn heavily influenced endocrine pathways . androgen deprivation therapy-induced hypogonadism results negative effects skeletal muscle health. prospective longitudinal study involving 252 men adt median 20.4 months reported lean body mass decreases progressively three years; 1.0% one year, 2.1% two years, 2.4% three years appears pronounced men ≥ 70 years age . 8.2.5.5. cardiovascular morbidity cardiovascular mortality common cause death pca patients . several studies showed adt six months associated increased risk diabetes mellitus, cardiovascular disease, myocardial infarction . rtog 92-02 94-08 trials confirmed increased cardiovascular risk, unrelated duration adt accompanied overall increased cardiovascular mortality. increase cardiovascular mortality reported secondary analysis plco trial, even among subgroups pre-existing cardiovascular disease meta-analysis trials rtog 8531, 8610, 9202, eortc 30891 eortc 22863 . however, serious concerns conclusions meta-analysis raised due poor consideration bias included studies . meta-analysis observational data reports consistent links adt risk cardiovascular disease patients treated pca, e.g., associations lhrh agonists non-fatal fatal myocardial infarction stroke rr: 1.57 (95% ci: 1.26–1.94) rr: 1.51 (95% ci: 1.24–1.84), respectively . updated meta-analysis cardiometabolic effects adt, adt associated metabolic syndrome rr: 1.60 (95% ci: 1.06-2.42), lower association diabetes rr 1.43 (95% ci: 1.28-1.59) previously reported, increased risk hypertension 30%, rr 1.30 (95% ci: 1.08-1.55). adjustment publication bias adt associated 25% increased risk diabetes associated metabolic syndrome . increase cardiovascular mortality reported patients suffering previous congestive heart failure myocardial infarction retrospective database analysis presenting metabolic syndrome . suggested antagonists might associated less cardiovascular morbidity compared agonists, but, yet definite evidence . phase iii rct use relugolix, oral lhrh antagonist, associated reduced risk major adverse cardiovascular events compared leuprolide, injectable lhrh agonists, 2.9% vs. 6.2%, respectively, follow-up time 48 weeks (hr 0.46, 95% ci: 0.24–0.88) . concerns lhrh agonists resulted fda warning consensus paper american heart, cancer society urological associations . preventive advice includes non-specific measures loss weight, increased exercise, minimising alcohol intake, improved nutrition smoking cessation . adverse-effects different artas (abiraterone, apalutamide, darolutamide, enzalutamide) treatment mcrpc, nmcrpc, mhspc systematically reviewed multi-variate network meta-analysis. suggested artas adverse effect profiles significantly differ other, except enzalutamide ranked toxic regarding hypertension mcrpc nmcrpc, toxic regarding headache across prostate cancer settings . 8.2.5.6. fatigue fatigue often develops side effect adt. regular exercise appears best protective measure. reporting clinically significant fatigue associated severe psychological distress prompt screening anxiety and/or depression . anaemia may cause fatigue . anaemia requires aetiological diagnosis (medullar invasion, renal insufficiency, iron deficiency, chronic bleeding) individualised treatment. regular blood transfusions may required patients severe anaemia. 8.2.5.7. neurological side effects castration seems also associated increased risk stroke , suspected associated increased risk depression cognitive decline alzheimer disease . 8.2.5.8. osteonecrosis bisphosphonates denosumab bisphosphonates synthetic pyrophosphate analogs used conditions malignancy osteoporosis. infrequent side effects associated bisphosphonate use include pyrexia, renal function impairment, hypocalcemia, avascular osteonecrosis jaw. denosumab human monoclonal antibody used treatment osteoporosis bone metastasis . acts inhibiting osteoclast activity, reducing bone resorption, increasing bone density . highly specific mechanism action inhibition receptor activator nuclear factor-kappa b ligand (rankl). shown effective increasing bone mineral density decreasing fractures men prostate cancer adt . drugs associated osteonecrosis jaw (onj) according american society bone mineral research, onj described exposed bone maxillofacial region heal within eight weeks identified healthcare provider patient currently bisphosphonates history radiation therapy craniofacial region . incidence onj related dose duration treatment. risk ranges greater 1% twelve months 11% four years treatment - taking zoledronic acid alone increases risk osteonecrosis 21% third year. sr denosumab showed total 8,963 patients variety solid tumours seven randomised controlled trials (rcts) overall incidence onj patients cancer receiving denosumab 1.7% [95% ci: 0.9–3.1%]. use denosumab associated significantly increased risk onj comparison bisphosphonates (bps)/placebo treatment (rr 1.61, 95% ci: 1.05–2.48, p = 0.029). subgroup analysis based controlled therapies demonstrated increased risk onj denosumab therapy, compared bps (rr 1.48, 95% ci: 0.96–2.29, p = 0.078) placebo (rr 16.28, 95% ci: 1.68–158.05, p = 0.017). similar results observed prostate cancer (rr 3.358, 95% ci: 1.573–7.166, p = 0.002). denosumab combined risk factors dental extraction, poor oral hygiene, use removable apparatus, chemotherapy may favour development onj. therefore, starting drugs patients undergo dental examination maintain good oral hygiene.